The device will be used for later treatment of osteoarthritis and diabetic foot ulcer to even breast augmentation surgery
Bengaluru-based Stempeutics Research plans to launch its innovative stem cell medical device ‘Stempeutron’ in India by the middle of next year subject to regulatory approvals.
The device, which can obtain a population of cells collectively known as the stromal vascular fraction (SVF) from fat tissues, to be used for later treatment of osteoarthritis and diabetic foot ulcer to even breast augmentation surgery, is estimated to be priced at $50,000.
“We plan to launch our novel device Stempeutron in India by middle of next year as soon as we get regulatory nod for it. It will be launched in multiple hospitals across the country before it goes global,” BN Manohar, Managing Director and Chief Executive Officer, Stempeutics.
The company is looking for a strategic partner to globalise and market this device in India and outside. The device will be launched first in India, followed by South East Asia and then Europe and US, he said, adding the estimated selling price of the consumables would be $1,000.
“We have already received go ahead from Cipla to either sell the product or to enter into a partnership with a big player to commercialise the device,” Manohar said.
Comments are closed.